EVOCAL Health selected for Plug & Play's global acceleration program STARTUP CREASPHERE
EVOCAL Health part of the global digital health program STARTUP CREASPHERE powered by Plug & Play
Hamburg/Munich (Germany), October 7, 2021: EVOCAL Health, a biopharmaceutical digital health company unlocking the human voice as a biomarker for AI-based detection and treatment of diseases (so-called vocal biomarkers), today announced to be selected for Plug & Play's global acceleration program STARTUP CREASPHERE.
Established by Roche and the iconic Silicon Valley-based venture capital investor and corporate innovation provider Plug and Play in 2018, the international Startup Creasphere program unites healthcare innovators from around the globe to build solutions for the future of healthcare.
By connecting global healthcare innovators such as corporates, startups, investors, providers, payers, and users, in the three locations in Munich, Singapore and Silicon Valley, Plug and Play has established a global innovation platform within the healthcare ecosystem aimed to accelerate the development of new digital health solutions and business models. As one of seven startups, EVOCAL Health has been selected from over 300 applicants worldwide to join the dedicated pilot-driven program to accelerate success in unlocking the human voice as a biomarker and to be supported in business development.
EVOCAL Health Co-Founder and CEO/COO Philip Mertes: "Transforming healthcare in the 21st century is all about building synergetic partnerships between global players and innovators around the globe. We are delighted to be selected internationally and now being part of Plug and Play's global ecosystem to continue working on overcoming the most pressing challenges in healthcare together."